NCT03445533 2022-11-08A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory MelanomaIdera Pharmaceuticals, Inc.Phase 3 Terminated481 enrolled 22 charts
NCT03354962 2020-12-04Induction of Immune-mediated aBscOpal Effect thrOugh STEreotactic Radiation Therapy in Metastatic Melanoma Patients Treated by PD-1 + CTLA-4 Inhibitors (BOOSTER MELANOMA)Institut Claudius RegaudPhase 1/2 Terminated6 enrolled